The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
BUSINESS
Taking on Solid Tumors - 2: Chugai Poised to Break through Solid Cancer “Wall” with Trispecific Antibodies
After introducing bispecific antibodies for hemophilia and ophthalmic diseases, Chugai Pharmaceutical has started expanding the modality into the oncology space with the launch of a blood cancer drug this spring. For solid tumors, the Roche group company looks to blaze…
To read the full story
Related Article
- Taking on Solid Tumors - 5: Genmab Pursuing Unique T-Cell Engager Program for Lung Cancer
June 11, 2025
- Taking on Solid Tumors - 4: With 2 Late-Stage Assets in Wings, Will AstraZeneca Reshape CP Inhibitor Landscape?
June 10, 2025
- Taking on Solid Tumors - 3: J&J to Soon Have 3 Bispecifics in Japan as Rybrevant Gathers Pace
May 30, 2025
- Taking on Solid Tumors - 1: Japan Sees Rush of Bispecific Approvals with Good Progress in Blood Cancers, and More
May 27, 2025
BUSINESS
- Chugai Halts Dosing of Non-Ambulatory Patients in DMD Gene Therapy Trial after 2 Deaths Overseas
June 17, 2025
- Astellas, MRI Join Hands to Support Startups via MEDISO
June 17, 2025
- Maruishi Takes Over Bayer’s Sleep Inducer Evamyl in Japan
June 17, 2025
- Mitsubishi’s BRD4 Degrader Now in US PI/II for Solid Tumors
June 16, 2025
- Sumitomo’s Myelofibrosis Drug Earns Fast-Track Tag in US
June 16, 2025
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…